07/08/2025
💙 In conjunction with the launch of T-DXd in lung cancer, Dr Joline Lim was invited to launch events held from 24th to 26th July 2025 in Johor Bahru, Malacca, and Kuala Lumpur.
These sessions brought together 🩺 medical oncology specialists, 🩷 breast and lung surgeons, 🧪 pathologists, and other healthcare professionals to exchange expertise on the evolving landscape of HER2-low breast cancer treatment and HER2 mutant lung cancers.
🎯 The breast cancer program focused on highlighting the sequencing of T-DXd in the HER2-low space and its clinical implications, as well as emphasizing the shift from binary HER2 reporting to a broader HER2 spectrum, a critical advancement in breast cancer diagnostics and treatment strategy.
📢 During the sessions, Dr. Joline delivered a presentation on “Breast Cancer: Shifting Perspectives in HER2 Treatment” and joined the expert panel discussion, sharing valuable insights and exchanging best practices with our colleagues from various regions in Malaysia.
🙏 We extend our sincere appreciation to AstraZeneca for organizing this impactful program, and to all the medical professionals who contributed to meaningful discussions that will help shape the future of breast cancer management in Malaysia.
